ALT vs CTMX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ALT · Altimmune$2.08 ▲ 5.58%
CTMX · CytomX$2.19 ▲ 2.34%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ALT -51.2%
- CTMX -47.7%
Head to head
| Metric | ALT | CTMX |
|---|---|---|
| Price | $2.08 | $2.19 |
| Change today | ▲ 5.58% | ▲ 2.34% |
| Market cap | $404.60M | $477.43M |
| Return, 3 months | -31.8% | -36.3% |
| Return, year to date | -42.4% | -48.6% |
| Return, 1 year | -49.4% | -39.5% |
| P/E (TTM) | – | – |
| P/B | 0.9 | 1.7 |
| P/E percentile vs own 5y | 83rd | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | -92.4% |
| Net profit growth (YoY) | -3.1% | -13,319.5% |
| Gross margin | – | – |
| Operating margin | -323,306.5% | -476.2% |
| Net margin | -296,000.0% | -435.2% |
| Return on equity | -28.9% | -37.8% |
| Analyst target vs. price | +813.5% | +493.6% |
| Analyst buy share | 75% | 100% |
| RSI (14) | 37 | 41 |
| 30-day volatility | 50.3% | 67.9% |
| Max drawdown, 1 year | -68.1% | -68.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTMX is the largest of the group by market value.
- CTMX has returned the most over the past year.
- CTMX is growing revenue fastest.
- CTMX keeps the most profit per dollar of sales.
- ALT has been the calmest stock over the last 30 days.